Market Overview:
Epidermolysis bullosa (EB) is a group of rare genetic disorders that cause easy blistering of the skin and mucous membranes. The major types of EB are recessive dystrophic EB, dominant dystrophic EB, junctional EB and Kindler syndrome. Some major symptoms of EB include blistering, itching or burning sensation, scarring and disfigurement. The global EB market growth is driven by increasing research for effective treatments and therapies. Cell therapy and gene therapy are some of the promising treatment approaches currently being researched. Growing awareness initiatives by non-profit organizations is also supporting the market growth.
The global Epidermolysis Bullosa Market is estimated to be valued at US$ 3,429.30 Mn in 2023 and is expected to exhibit a CAGR of 11% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Get more insights on this topic: https://www.coherentmarketinsights.com/market-insight/epidermolysis-bullosa-therapeutics-market-2214
Market key trends:
One of the key market trends is increasing research funding for EB treatment. For instance, Department of Defense Congressionally Directed Medical Research Programs granted funding of US$ 15 million for EB research in 2020. Another major trend is the availability of pipeline drugs and therapies. Some of the therapies in pipeline are BPX-501 for recessive dystrophic EB, KB103 for recessive dystrophic EB and JNCC-01 for junctional EB. Advancements in cell and gene therapy approaches also offer potential treatment options. Growing clinical trials testing novel therapies will drive the market during the forecast period.
Porter’s Analysis
Threat of new entrants: Low entry barriers in terms of required capital investment and technology offer threat of new companies entering the epidermolysis bullosa market. However, established brand loyalty and need for extensive research and regulatory approvals for new treatments pose challenges for new entrants.
Bargaining power of buyers: End-users of epidermolysis bullosa treatment have moderate bargaining power due to presence of many established players and availability of alternative treatment options. However, critical nature of the rare disease increases customer dependence on available therapies.
Bargaining power of suppliers: Presence of differentiated raw material and technology suppliers for treatment development provides them higher bargaining power over manufacturers in terms pricing and contracts. Established relationships between suppliers and established players balance this effect to some extent.
Threat of new substitutes: Limited therapeutic alternatives and innovations in epidermolysis bullosa treatment development pose low threat of substitutes. However, new drug development and combination therapies are expected to challenge current market shares in long run.
Competitive rivalry: Intense competition exists among treatment manufacturers to gain higher market share through continuous innovations, new drug development, and strategic collaborations.
Key Takeaways
The global epidermolysis bullosa market is expected to witness high growth, exhibiting CAGR of 11.% over the forecast period, due to increasing research funding and regulatory approvals for new therapies.
The market size for 2023 is estimated to be US$ 3,429.30 Mn. North America is expected to dominate the global market during the forecast period, owing to rising awareness about rare diseases, availability of advanced healthcare facilities, and robust research funding in the region.
Key players operating in the epidermolysis bullosa market are Amryt Pharma, Abeona Therapeutics, Castle Creek Pharmaceuticals, RegeneRx, Krystal Biotech, RHEACELL GmbH, Holostem Terapie Avanzate, StemRim/Shionogi, and Phoenix Tissue Repair. Amryt Pharma and Abeona Therapeutics are leading the clinical research and development of novel gene and stem cell therapies. Other players are focusing on therapies combining different treatment modalities.
